[1]施东华,翟 博,沈加林.经皮胆道支架联合近距内放疗治疗不能手术切除的肝门胆管癌 [J].介入放射学杂志,2017,(03):243-248.
 SHI Donghua,ZHAI Bo,SHEN Jialin.Percutaneous biliary stenting combined with brachytherapy for the treatment of unresectable Klatskin’s tumor[J].journal interventional radiology,2017,(03):243-248.
点击复制

经皮胆道支架联合近距内放疗治疗不能手术切除的肝门胆管癌 ()

PDF下载中关闭

分享到:

《介入放射学杂志》[ISSN:1008-794X/CN:31-1796/R]

卷:
期数:
2017年03期
页码:
243-248
栏目:
非血管介入
出版日期:
2017-03-25

文章信息/Info

Title:
Percutaneous biliary stenting combined with brachytherapy for the treatment of unresectable Klatskin’s tumor
作者:
施东华 翟 博 沈加林
Author(s):
SHI Donghua ZHAI Bo SHEN Jialin
Department of Interventional Oncology, Affiliated Renji Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai 200127, China
关键词:
【关键词】 肝门胆管癌 梗阻性黄疸 胆道支架 近距放疗 125I粒子
文献标志码:
A
摘要:
【摘要】 目的 探讨经皮胆道支架联合近距内放疗治疗不能手术切除的肝门胆管癌的可行性、安全性和有效性,以及联合治疗对患者黄疸复发和生存期的影响。方法 对2014年2月—2015年12月上海仁济医院肿瘤介入科收治的21例不能手术切除而接受经皮胆道支架联合近距内放疗的肝门胆管癌患者及该院同期单纯胆道引流或金属裸支架植入的患者28例进行回顾性分析。观察手术成功率、退黄效果及术后并发症发生率,比较两组患者生存期和黄疸复发时间的差异。结果 21例联合治疗患者共植入金属裸支架32枚,放射性125I粒子580颗,手术成功率100%,治疗有效率85.7%,术后早期并发症发生率9.5%,无手术相关死亡发生。联合治疗组患者术后中位黄疸复发时间为344 d而单纯胆道引流或金属裸支架植入患者的中位黄疸复发时间为193 d(P=0.035)。联合治疗组患者中位生存期387 d明显长于单纯胆道引流或金属裸支架植入患者的256 d(P=0.022)。结论 经皮胆道支架联合近距离内放疗作为不能手术切除的肝门胆管癌患者的姑息治疗方案安全有效可行,联合治疗能够推迟肝门胆管癌患者的黄疸复发及延长生存期。

参考文献/References:

[1] Shaib Y, El- Serag HB. The epidemiology of cholangiocarcinoma[J]. Semin Liver Dis, 2004, 24: 115-125.
[2] Shaib YH, Davila JA, McGlynn K, et al. Rising incidence of intrahepatic cholangiocarcinoma in the United States: a true increase?[J]. J Hepatol, 2004, 40: 472- 477.
[3] Bridgewater J, Galle PR, Khan SA, et al. Guidelines for the diagnosis and management of intrahepatic cholangiocarcinoma[J]. J Hepatol, 2014, 60: 1268-1289.
[4] Vauthey JN, Blumgart LH. Recent advances in the management of cholangiocarcinomas[J]. Semin Liver Dis, 1994, 14: 109-114.
[5] Gatto M, Bragazzi MC, Semeraro R, et al. Cholangiocarcinoma: update and future perspectives[J]. Dig Liver Dis, 2010, 42: 253- 260.
[6] Ghouri YA, Mian I, Blechacz B. Cancer review: cholangiocarcinoma[J]. J Carcinog, 2015, 14: 1.
[7] Yao D, Kunam VK, Li X. A review of the clinical diagnosis and therapy of cholangiocarcinoma[J]. J Int Med Res, 2014, 42: 3-16.
[8] Khan SA, Toledano MB, Taylor- Robinson SD. Epidemiology, risk factors, and pathogenesis of cholangiocarcinoma[J]. HPB (Oxford), 2008, 10: 77- 82.
[9] Patel T. Increasing incidence and mortality of primary intrahepatic cholangiocarcinoma in the United States[J]. Hepatology, 2001, 33: 1353- 1357.
[10] Patel T. Worldwide trends in mortality from biliary tract malignancies[J]. BMC Cancer, 2002, 2: 10.
[11] Nathan H, Aloia TA, Vauthey JN, et al. A proposed staging system for intrahepatic cholangiocarcinoma[J]. Ann Surg Oncol, 2009, 16: 14-22.
[12] de Jong MC, Nathan H, Sotiropoulos GC, et al. Intrahepatic cholangiocarcinoma: an international multi- institutional analysis of prognostic factors and lymph node assessment[J]. J Clin Oncol, 2011, 29: 3140- 3145.
[13] Mosconi S, Beretta GD, Labianca R, et al. Cholangiocarcinoma[J]. Crit Rev Oncol Hematol, 2009, 69: 259- 270.
[14] Valle JW. Advances in the treatment of metastatic or unresectable biliary tract cancer[J]. Ann Oncol, 2010, 21(Suppl 7): vii345-vii348.
[15] Cunningham SC, Choti MA, Bellavance EC, et al. Palliation of hepatic tumors[J]. Surg Oncol, 2007, 16: 277- 291.
[16] Khan SA, Thomas HC, Davidson BR, et al. Cholangiocarcinoma[J]. Lancet, 2005, 366: 1303-1314.
[17] Zechlinski JJ, Rilling WS. Transarterial therapies for the treatment of intrahepatic cholangiocarcinoma[J]. Semin Intervent Radiol, 2013, 30: 21- 27.
[18] 韩成龙, 马亦龙, 欧盛秋, 等. 125I粒子条联合胆道支架植入治疗恶性梗阻性黄疸22例疗效分析[J]. 介入放射学杂志, 2015, 24: 141- 145.
[19] Ling CC, Yorke ED, Spiro IJ, et al. Physical dosimetry of 125I seeds of a new design for interstitial implant[J]. Int J Radiat Oncol Biol Phys, 1983, 9: 1747- 1752.
[20] 吴林霖, 颜志平, 张 雯, 等. 经动脉灌注化疗联合125I粒子条治疗原发性肝癌合并门脉癌栓的疗效分析[J]. 介入放射学杂志, 2015, 24: 776- 780.
[21] Paik WH, Park YS, Hwang JH, et al. Palliative treatment with self- expandable metallic stents in patients with advanced type Ⅲ or Ⅳ hilar cholangiocarcinoma: a percutaneous versus endoscopic approach[J]. Gastrointest Endosc, 2009, 69: 55- 62.
[22] Pinol V, Castells A, Bordas JM, et al. Percutaneous self-expanding metal stents versus endoscopic polyethylene endopros- theses for treating malignant biliary obstruction: randomized clinical trial[J]. Radiology, 2002, 225: 27- 34.
[23] Inal M, Akgul E, Aksungur E, et al. Percutaneous self- expandable uncovered metallic stents in malignant biliary obstruction. Complications, follow- up and reintervention in 154 patients[J]. Acta Radiol, 2003, 44: 139- 146.
[24] Hochwald SN, Burke EC, Jarnagin WR, et al. Association of preoperative biliary stenting with increased postoperative infectious complications in proximal cholangiocarcinoma[J]. Arch Surg, 1999, 134: 261- 266.
[25] Isayama H, Tsujino T, Nakai Y, et al. Clinical benefit of radiation therapy and metallic stenting for unresectable hilar cholangiocarcinoma[J]. World J Gastroenterol, 2012, 18: 2364-2370.

相似文献/References:

[1]王小林.胆道支架的进展与开发[J].介入放射学杂志,1998,(03):129.
[2]尹卫民,周建新,谢敏,等.经皮肝穿植入胆道内支架治疗胆道狭窄[J].介入放射学杂志,1995,(04):192.
[3]牛洪涛,翟仁友,王剑锋,等.胃癌合并梗阻性黄疸经皮经肝胆道引流术后中、长期疗效分析[J].介入放射学杂志,2011,(03):227.
 NIU Hong-tao,ZHAI Ren-you,WANG Jian-feng,et al.PTBD for the treatment of malignant obstructive jaundice associated with gastric cancer: an analysis of middle-term and long-term efficacy[J].journal interventional radiology,2011,(03):227.
[4]杨顺春,顾海燕,徐骁,等.经皮肝穿刺胆道造影在老年梗阻性黄疸病因诊断中的应用[J].介入放射学杂志,2000,(02):93.
[5]程 龙,靳 勇,白旭明,等. 经皮经肝胆道引流术后胆道感染的相关因素分析[J].介入放射学杂志,2012,(06):509.
 CHENG Long,JIN Yong,BAI Xu- ming,et al. Biliary infection occurred after percutaneous transhepatic biliary drainage: an analysis of the related factors[J].journal interventional radiology,2012,(03):509.
[6]赵晓阳,曹会存,李天晓,等. 经皮肝穿胆道引流术联合125I粒子植入治疗晚期胰腺癌合并梗阻性黄疸[J].介入放射学杂志,2013,(08):650.
 ZHAO Xiao? yang,CAO Hui? cun,LI Tian? xiao,et al. PTCD combined with 125I seed implantation for the treatment of advanced pancreatic cancer associated with obstructive jaundice[J].journal interventional radiology,2013,(03):650.
[7]金 壮,曹军英,张 筠,等.超声引导下PTCD与ERCP联合治疗恶性梗阻性黄疸十例[J].介入放射学杂志,2015,(03):223.
 JIN Zhuang,CAO Jun ying,ZHANG Yun,et al.Ultrasound guided PTCD combined with ERCP for the treatment of malignant obstructive jaundice: initial experience in 10 cases[J].journal interventional radiology,2015,(03):223.
[8]任建庄,张 凯,李腾飞,等.中下段胆总管癌致恶性梗阻性黄疸介入治疗疗效分析[J].介入放射学杂志,2015,(05):409.
 REN Jian zhuang,ZHANG Kai,LI Teng fei,et al.Interventional therapy for malignant obstructive jaundice caused by cholangiocarcinoma located at middle low segment of common bile duct: analysis of curative effect[J].journal interventional radiology,2015,(03):409.
[9]张金星,祖庆泉,施海彬.金属支架治疗胰腺癌合并梗阻性黄疸42例预后分析 [J].介入放射学杂志,2018,27(04):366.
 ZHANG Jinxing,ZU Qingquan,SHI Haibin.Percutaneous metal stent implantation for the treatment of pancreatic cancer associated with obstructive jaundice: prognostic analysis of 42 patients[J].journal interventional radiology,2018,27(03):366.
[10]邱岚茜,邱 燕,蒋 蕾,等.辅助125I粒子植入器械包联合腹部125I粒子植入防护铅褂在恶性梗阻性黄疸125I粒子支架植入患者中的应用及效果[J].介入放射学杂志,2020,29(08):829.
 QIU Lanxi,QIU Yan,JIANG Lei,et al.The application of self-made auxiliary 125I seed implantation device package and abdominal 125I seed implantation protective lead apron in biliary 125I seed stent implantation for malignant obstructive jaundice[J].journal interventional radiology,2020,29(03):829.

备注/Memo

备注/Memo:
(收稿日期:2016-07-26)
(本文编辑:俞瑞纲)
更新日期/Last Update: 2017-03-14